Death associated with CMV disease · solid organ transplant recipients
Ganciclovir showed no clear difference in death due to CMV disease compared with aciclovir (moderate certainty).
1 finding from 1 review
All‐cause death · solid organ transplant recipients
Ganciclovir showed no clear difference in all‐cause death compared with aciclovir (moderate certainty).
1 finding from 1 review
Acute rejection · solid organ transplant recipients
Ganciclovir showed no clear difference in acute rejection compared with aciclovir (high certainty).
1 finding from 1 review
Graft loss · solid organ transplant recipients
Ganciclovir showed no clear difference in graft loss compared with aciclovir (moderate certainty).
1 finding from 1 review
Opportunistic infections: other viral infections · solid organ transplant recipients
Ganciclovir showed no clear difference in opportunistic infections: other viral infections compared with aciclovir (moderate certainty).
1 finding from 1 review
Leucopenia · solid organ transplant recipients
Ganciclovir may leads to higher leucopenia compared with aciclovir (low certainty).
1 finding from 1 review
Kidney dysfunction · solid organ transplant recipients
Ganciclovir showed no clear difference in kidney dysfunction compared with aciclovir (moderate certainty).
1 finding from 1 review
CMV disease · solid organ transplant recipients
Ganciclovir leads to lower CMV disease compared with aciclovir (high certainty).
1 finding from 1 review
CMV disease · solid organ transplant recipients
Valaciclovir showed no clear difference in CMV disease compared with ganciclovir or valganciclovir (low certainty).
1 finding from 1 review
All‐cause death · solid organ transplant recipients
Valaciclovir showed no clear difference in all‐cause death compared with ganciclovir or valganciclovir (low certainty).
1 finding from 1 review
CMV infection · solid organ transplant recipients
Valaciclovir showed no clear difference in CMV infection compared with ganciclovir or valganciclovir (low certainty).
1 finding from 1 review
Acute rejection · solid organ transplant recipients
It is very uncertain whether valaciclovir changes acute rejection compared with ganciclovir or valganciclovir (very low certainty).
1 finding from 1 review
Graft loss · solid organ transplant recipients
Valaciclovir showed no clear difference in graft loss compared with ganciclovir or valganciclovir (low certainty).
1 finding from 1 review
Leucopenia · solid organ transplant recipients
Valaciclovir showed no clear difference in leucopenia compared with ganciclovir or valganciclovir (moderate certainty).
1 finding from 1 review
SCr at the end of · solid organ transplant recipients
1 finding from 1 review
CMV disease · solid organ transplant recipients
Extended probably leads to lower CMV disease compared with short‐duration valganciclovir (moderate certainty).
1 finding from 1 review
All‐cause death · solid organ transplant recipients
Extended showed no clear difference in all‐cause death compared with short‐duration valganciclovir (low certainty).
1 finding from 1 review
CMV syndrome · solid organ transplant recipients
Extended probably leads to lower CMV syndrome compared with short‐duration valganciclovir (moderate certainty).
1 finding from 1 review
CMV infection · solid organ transplant recipients
Extended may leads to lower CMV infection compared with short‐duration valganciclovir (low certainty).
1 finding from 1 review
Acute rejection · solid organ transplant recipients
Extended probably leads to lower acute rejection compared with short‐duration valganciclovir (moderate certainty).
1 finding from 1 review